ZURICH, Feb 13 (Reuters) - Sandoz, the generic unit of Swiss drugmaker Novartis AG, said it has received European Commission approval for biosimilar filgrastim. Filgrastim is indicated for the treatment of neutropenia, a condition characterized by a lack of neutrophils, one of the most common types of white blood cells, whose role is to fight infection in the body.
